Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 912029 | ISIN: US31428X1063 | Ticker-Symbol: FDX
Tradegate
06.06.25 | 16:48
192,22 Euro
+1,45 % +2,74
1-Jahres-Chart
FEDEX CORPORATION Chart 1 Jahr
5-Tage-Chart
FEDEX CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
192,94193,3218:12
192,90193,3618:12
ACCESS Newswire
232 Leser
Artikel bewerten:
(1)

FedEx Global Healthcare Secures IATA CEIV Pharma Corporate Certificate

MIAMI, FL / ACCESS Newswire / June 5, 2025 / FedEx becomes first global integrator to achieve CEIV Pharma certification for ground handling across its air hubs and ramps.

FedEx Corp. (NYSE:FDX) announced that at the 34th CNS Partnership Conference, the International Air Transport Association (IATA) recognized the FedEx Global Healthcare Quality Program with the CEIV Pharma Corporate Certification - a significant milestone in the company's commitment to quality, compliance, and leadership in pharmaceutical logistics. This corporate-level certificate for the company's hubs and ramps validates the strength of FedEx's quality management system and its ability to deliver end-to-end logistic services in compliance with the increasingly complex and highly regulated pharmaceutical industry.

"This certification illustrates FedEx's unwavering dedication to excellence in pharmaceutical logistics," said Nick Gennari, president of global healthcare and commercial sales. "This pioneering, network-wide approach to quality showcases our commitment to complying with the highest standards in the industry for the transportation and handling of global pharmaceutical products. With over 90 percent of our global healthcare volume moving through facilities that are now CEIV Pharma-certified, we are providing our customers with outstanding quality solutions in the global pharma air space."

The Center of Excellence for Independent Validators (CEIV) Pharma Certification sets the highest standards for the safe, compliant, and time sensitive temperature-controlled transport of pharmaceutical shipments across global air cargo network.

"The pharmaceutical industry relies on air transport for its speed and efficiency in ensuring high-value, time-sensitive, temperature-controlled products such as vaccines or medication. As global supply chains become more complex, the need for consistent, trusted standards is greater than ever for the safety of the end consumers. We are pleased to see FedEx Global Healthcare certify additional facilities with CEIV Pharma, the industry's trusted mark of quality and excellence in the handling of pharmaceuticals," said Frederic Leger, IATA's senior vice president commercial products and services.

FedEx previously had its Memphis (MEM) and Indianapolis (IND) hubs CEIV Pharma-certified in 2024, along with ramps in San Juan (SJU) and Aguadilla (BQN), Puerto Rico. In addition to the corporate certificate, the FedEx Global Healthcare team also announced 15 new CEIV Pharma certified facilities, all of which will be officially certified in May 2025:

  • Cologne, Germany (CGN)

  • Fort Worth, Texas (AFW)

  • Frankfurt, Germany (FRA)

  • Greensboro, North Carolina (GSO)

  • Guangzhou, China (CAN)

  • Liege, Belgium (LGG)

  • Los Angeles, California (LAX)

  • Miami, Florida (MIA)

  • Milan, Italy (MXP)

  • Newark, New Jersey (EWR)

  • Oakland, California (OAK)

  • Osaka, Japan (KIX)

  • Paris, France (CDG)

  • San Jose, Costa Rica (SJO)

  • Santo Domingo, Dominican Republic (SDQ)

About FedEx Corp.
FedEx Corp. (NYSE:FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce, and business services. With annual revenue of $88 billion, the company offers integrated business solutions utilizing its flexible, efficient, and intelligent global network. Consistently ranked among the world's most admired and trusted employers, FedEx inspires its more than 500,000 employees to remain focused on safety, the highest ethical and professional standards, and the needs of their customers and communities. FedEx is committed to connecting people and possibilities around the world responsibly and resourcefully, with a goal to achieve carbon-neutral operations by 2040. To learn more, please visit fedex.com/about.

Click here to learn about FedEx Cares, our global community engagement program.


View additional multimedia and more ESG storytelling from FedEx on 3blmedia.com.

Contact Info:
Spokesperson: FedEx
Website: https://www.3blmedia.com/profiles/fedex
Email: info@3blmedia.com

SOURCE: FedEx



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/transportation/fedex-global-healthcare-secures-iata-ceiv-pharma-corporate-certificate-1036014

© 2025 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.